- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00184821
Ischemic Injury and Ischemic Preconditioning in Diabetes
Acute Local Ischemic Preconditioning in Patients With Type 1 Diabetes in Vivo
In this proof-of-concept study, forearm vulnerability to ischemic exercise is studied in patients with type 1 diabetes mellitus with and without prior ischemic preconditioning (short period of ischemia that protects against subsequent ischemic exercise). Annexin A5 scintigraphy is used to quantify subtle signs of mild and reversible forearm injury that results from ischemic exercise.
The following hypotheses are tested:
- Patients with type 1 diabetes are not more vulnerable to ischemic injury as compared with previously studied healthy volunteers.
- Ischemic preconidtioning is still present in patients with type 1 diabetes. Depending on the validity of hypothesis 2, the effect of short pharmacological interventions are studied on vulnerability to forearm ischemia/reperfusion injury in the absence or presence of local forearm ischemic preconditioning.
Study Overview
Status
Detailed Description
All patients will be studied in supine position after an overnight fast, while plasma glucose levels are monitored. In the first 8 patients intravenous insulin is administered as needed, to reach target glucose levels between 5-7 mmol/l. Patients will be subjected to 10 minutes of forearm ischemia (non-dominant arm), combined with handgripping at 50% of maximal force until exhaustion. Upon reperfusion, Tc-99m-HYNIC-Annexin A5 will be injected intravenously. Targeting of annexin A5 to thenar muscle and forearm flexor muscle will be quantified as the percentage difference in radioactivity between experimental and control side. This procedure will be performed twice (randomized cross-over design), with at least 2 week interval, either with or without 10 minutes ischemia followed by 10 minutes of reperfusion prior to ischemic exercise.
Depending on the results of this study, substudies will be performed to study the effect of diazoxide (K-ATP channel opener, may mimic ischemic preconditioning), glibenclamide (K-ATP channel blocker, may inhibit ischemic preconditioning) or adenosine (infusion into brachial artery of non-dominant arm as a substitute for ischemic preconditioning).
Study Type
Enrollment
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500 HB
- Clinical Research Centre Nijmegen; Radboud University Nijmegen Medical Centre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- type 1 diabetes mellitus
- age 18-50 years
Exclusion Criteria:
- hypertension (systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90 mmHg
- cardiovascular disease (coronary artery insufficiency,CVA/TIA, peripheral artery disease
- HbA1c > 9%
- Body Mass Index < 25 kg/m2
- Unable to stop co-medication (other than insulin) for 1 week
- Previous exposure to radiation (diagnostic or therapeutic) in the past year
Study Plan
How is the study designed?
Design Details
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Richard Engbersen, MD, Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology
- Study Chair: Gerard Rongen, MD, PhD, Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology
- Study Chair: Wim Oyen, MD, PhD, Radboud University Nijmegen Medical Centre; Department of Nuclear Medicine
- Study Chair: Marc Mol, MD, PhD, Canisius Wilhelmina Ziekenhuis Nijmegen; Department of Internal Medicine
- Principal Investigator: Paul Smits, MD, PhD, Radboud University Nijmegen Medical Centre; Department of Pharmacology-Toxicology
- Study Chair: B. Bravenboer, MD, PhD, Catharina Hospital Eindhoven, Dept. of Internal Medicine
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Postoperative Complications
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Ischemia
- Reperfusion Injury
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Purinergic Agents
- Purinergic P1 Receptor Agonists
- Purinergic Agonists
- Diazoxide
- Adenosine
- Glyburide
- Annexin A5
Other Study ID Numbers
- QKF03-diab
- 2004.11.022
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Insulin-Dependent
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
Inha University HospitalCompletedNon Insulin Dependent Diabetes MellitusKorea, Republic of
-
Procter and GambleTerminatedNon-Insulin-dependent Diabetes MellitusUnited States
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
VeraLight, Inc.CompletedDiabetes Mellitus, Non-Insulin DependentUnited States
-
Samsung Medical CenterMinistry of Trade, Industry & Energy, Republic of Korea; Korea Evaluation Institute... and other collaboratorsCompletedDiabetes Mellitus | Insulin-dependent Diabetes Mellitus | Insulin HypoglycemiaKorea, Republic of
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedDiabetes Mellitus, Type II | Diabetes Mellitus, Non Insulin DependentUnited States, Poland, Bulgaria, India, Malaysia, Romania, Canada, Russian Federation, Argentina, Puerto Rico, Czech Republic, United Kingdom, Mexico
-
National Center for Complementary and Integrative...CompletedDiabetes Mellitus, Non-Insulin Dependent | Non-Insulin DependentUnited States
-
Merck Sharp & Dohme LLCCompletedDiabetes Mellitus, Non-Insulin-Dependent | Type 2 Diabetes Mellitus, Non Insulin Dependent
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
Clinical Trials on Diazoxide
-
Johns Hopkins UniversityNot yet recruitingMyocardial StunningUnited States
-
Assistance Publique - Hôpitaux de ParisCompletedHypothalamic-pituitary Lesions | CraniopharyngiomasFrance
-
Virginia Commonwealth UniversityEunice Kennedy Shriver National Institute of Child Health and Human Development...Completed
-
Johns Hopkins UniversityWithdrawn
-
Grill, Valdemar, M.D.Completed
-
University of DundeeJuvenile Diabetes Research FoundationCompleted
-
Essentialis, Inc.WithdrawnHypertriglyceridemia
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...SuspendedDiabetes Mellitus, Type 2 | Glucose, High Blood | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Albert Einstein College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...Active, not recruitingGlucose Metabolism Disorders | Type 2 Diabetes | Glucose, High BloodUnited States